Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Share-based Compensation (2019 - 2025)

Historic Share-based Compensation for IDEAYA Biosciences (IDYA) over the last 7 years, with Q4 2025 value amounting to $11.8 million.

  • IDEAYA Biosciences' Share-based Compensation rose 2433.32% to $11.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $46.1 million, marking a year-over-year increase of 3272.03%. This contributed to the annual value of $46.1 million for FY2025, which is 3272.03% up from last year.
  • IDEAYA Biosciences' Share-based Compensation amounted to $11.8 million in Q4 2025, which was up 2433.32% from $12.2 million recorded in Q3 2025.
  • IDEAYA Biosciences' 5-year Share-based Compensation high stood at $12.2 million for Q3 2025, and its period low was $1.9 million during Q1 2021.
  • Over the past 5 years, IDEAYA Biosciences' median Share-based Compensation value was $4.8 million (recorded in 2023), while the average stood at $6.0 million.
  • Per our database at Business Quant, IDEAYA Biosciences' Share-based Compensation skyrocketed by 15303.43% in 2021 and then soared by 2192.32% in 2025.
  • IDEAYA Biosciences' Share-based Compensation (Quarter) stood at $2.1 million in 2021, then skyrocketed by 44.14% to $3.0 million in 2022, then skyrocketed by 61.28% to $4.8 million in 2023, then soared by 97.69% to $9.5 million in 2024, then grew by 24.33% to $11.8 million in 2025.
  • Its last three reported values are $11.8 million in Q4 2025, $12.2 million for Q3 2025, and $11.9 million during Q2 2025.